全文获取类型
收费全文 | 46490篇 |
免费 | 3633篇 |
国内免费 | 190篇 |
专业分类
耳鼻咽喉 | 575篇 |
儿科学 | 1014篇 |
妇产科学 | 964篇 |
基础医学 | 6475篇 |
口腔科学 | 1002篇 |
临床医学 | 4616篇 |
内科学 | 9538篇 |
皮肤病学 | 1080篇 |
神经病学 | 4479篇 |
特种医学 | 1979篇 |
外国民族医学 | 2篇 |
外科学 | 8547篇 |
综合类 | 475篇 |
一般理论 | 76篇 |
预防医学 | 2594篇 |
眼科学 | 921篇 |
药学 | 2779篇 |
中国医学 | 74篇 |
肿瘤学 | 3123篇 |
出版年
2023年 | 427篇 |
2022年 | 321篇 |
2021年 | 1486篇 |
2020年 | 1020篇 |
2019年 | 1347篇 |
2018年 | 1525篇 |
2017年 | 1027篇 |
2016年 | 1205篇 |
2015年 | 1389篇 |
2014年 | 1879篇 |
2013年 | 2190篇 |
2012年 | 3557篇 |
2011年 | 3502篇 |
2010年 | 1947篇 |
2009年 | 1736篇 |
2008年 | 2734篇 |
2007年 | 2784篇 |
2006年 | 2588篇 |
2005年 | 2408篇 |
2004年 | 2227篇 |
2003年 | 2029篇 |
2002年 | 1856篇 |
2001年 | 513篇 |
2000年 | 492篇 |
1999年 | 511篇 |
1998年 | 380篇 |
1997年 | 295篇 |
1996年 | 222篇 |
1995年 | 248篇 |
1994年 | 216篇 |
1993年 | 217篇 |
1992年 | 363篇 |
1991年 | 338篇 |
1990年 | 308篇 |
1989年 | 269篇 |
1988年 | 255篇 |
1987年 | 244篇 |
1986年 | 231篇 |
1985年 | 261篇 |
1984年 | 215篇 |
1983年 | 200篇 |
1982年 | 169篇 |
1981年 | 154篇 |
1980年 | 170篇 |
1979年 | 181篇 |
1978年 | 150篇 |
1977年 | 139篇 |
1976年 | 134篇 |
1974年 | 141篇 |
1973年 | 121篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
51.
Alexander Real Chierika Ukogu Divya Krishnamoorthy Nicole Zubizarreta Samuel K. Cho Andrew C. Hecht James C. Iatridis 《The spine journal》2019,19(2):225-231
Background Context
Low back pain (LBP) is a common complaint in clinical practice of multifactorial origin. Although obesity has been thought to contribute to LBP primarily by altering the distribution of mechanical loads on the spine, the additional contribution of obesity-related conditions such as diabetes mellitus (DM) to LBP has not been thoroughly examined.Purpose
To determine if there is a relationship between DM and LBP that is independent of body mass index (BMI) in a large cohort of adult survey participants.Study Design
Retrospective analysis of prospectively collected National Health and Nutrition Examination Survey (NHANES) data to characterize associations between LBP, DM, and BMI in adults subdivided into 6 subpopulations: normal weight (BMI 18.5–25), overweight (BMI 25–30), and obese (BMI >30) diabetics and nondiabetics. Diabetes was defined with glycohemoglobin A1c (HbA1c) ≥6.5%.Patient Sample
11,756 participants from NHANES cohort.Outcome Measures
Percentage of LBP reported.Methods
LBP reported in the 1999-2004 miscellaneous pain NHANES questionnaire was the dependent variable examined. Covariates included HbA1c, BMI, age, and family income ratio to poverty as continuous variables as well as race, gender, and smoking as binary variables. Individuals were further subdivided by weight class and diabetes status. Regression and graphical analyses were performed on the study population as a whole and also on subpopulations.Results
Increasing HbA1c did not increase the odds of reporting LBP in the full cohort. However, multivariate logistic regression of the 6 subpopulations revealed that the odds of LBP significantly increased with increasing HbA1c levels in normal weight diabetics. No other subpopulations reported significant relationships between LBP and HbA1c. LBP was also significantly associated with BMI for normal weight diabetics and also for obese subjects regardless of their DM status.Conclusions
LBP is significantly related to DM status, but this relationship is complex and may interact with BMI. These results support the concept that LBP may be improved in normal weight diabetic subjects with improved glycemic control and weight loss, and that all obese LBP subjects may benefit from improved weight loss alone. 相似文献52.
53.
Hester F Shieh Sarah A Tracy Charles R Hong Alexander V Chalphin Azra Ahmed Lucas Rohrer David Zurakowski Dario O Fauza 《Journal of pediatric surgery》2019,54(2):293-296
Purpose
Transamniotic stem cell therapy (TRASCET) with select mesenchymal stem cells (MSCs) has been shown to induce partial or complete skin coverage of spina bifida in rodents. Clinical translation of this emerging therapy hinges on its efficacy in larger animal models. We sought to study TRASCET in a model requiring intra-amniotic injections 60 times larger than those performed in the rat.Methods
Rabbit fetuses (n?=?65) with surgically created spina bifida were divided into three groups. One group (untreated) had no further manipulations. Two groups received volume-matched intra-amniotic injections of either saline or a concentrated suspension of amniotic fluid MSCs (afMSCs) at the time of operation. Infused afMSCs consisted of banked heterologous rabbit afMSCs with mesenchymal identity confirmed by flow cytometry, labeled with green fluorescent protein. Defect coverage at term was blindly categorized only if the presence of a distinctive neoskin was confirmed histologically. Statistical comparisons were by logistic regression and the likelihood ratio test.Results
Among survivors with spina bifida (n?=?19), there were statistically significant higher rates of defect coverage (all partial) in the afMSC group when compared with the saline and untreated groups (0–50%; p?=?0.022–0.036), with no difference between the saline and untreated groups (p?=?1.00). Donor afMSCs were identified locally, though sparsely and not in the neoskin.Conclusions
Concentrated intra-amniotic injection of amniotic mesenchymal stem cells can induce partial coverage of experimental spina bifida in a leporine model. Transamniotic stem cell therapy may become a feasible strategy in the prenatal management of spina bifida.Level of Evidence
N/A (animal and laboratory study). 相似文献54.
55.
56.
Sebastian P. Mondaca MD Dazhi Liu PharmD BCOP Jessica R. Flynn Sandy Badson Stefan Hamaway BS Mrinal M. Gounder MD Danny N. Khalil MD PhD Alexander E. Drilon MD Bob T. Li MD MPH Komal L. Jhaveri MD Alison M. Schram MD Katherine E. Kargus RN Mary Kate Kasler DNP MSN Natalie M. Blauvelt Neil H. Segal MD PhD Marinela Capanu PhD Margaret K. Callahan MD PhD David M. Hyman MD Maya Gambarin-Gelwan MD James J. Harding MD 《Cancer》2020,126(22):4967-4974
57.
Stefan Hatzl Florian Posch Alexander Deutsch Christine Beham-Schmid Herbert Stöger Hildegard Greinix Martin Pichler Peter Neumeister Katharina T. Prochazka 《Hematological oncology》2020,38(3):277-283
Overexpression of bcl-2 and c-myc are defining features of double-expressor-lymphoma (DEL) but may also occur separately in patients with primary central nervous system lymphoma (PCNSL). Despite all progress in optimizing treatment regimen, there is lack of sufficient risk stratification models. Here, we first describe the relationship between DEL biology, the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI), treatment response, disease progression, and mortality in PCNSL. In this study, we determined c-myc and bcl-2 status immunohistochemically in samples of 48 patients with newly diagnosed PCNSL and followed these patients for a median interval of 6.2 years. Twelve, 18, and 17 patients harbored none, one, or both DEL features. Corresponding overall response rates after first-line therapy were strongly associated with DEL biology (100%, 42%, and 44% in patients with 0, 1, or 2 DEL features). Patients with one or both DEL features had a 5-fold and 13-fold higher 5-year risk of progression and/or death than patients without DEL features. These associations prevailed after adjusting for the NCCN-IPI. DEL improved the discriminatory capability of the NCCN-IPI (P = .0001). Furthermore, we could show that addition of DEL biology to the NCCN-IPI significantly improved the score's discriminatory potential both toward progression-free survival (increase in Harell's c = 0.15, P = .005) and overall survival (increase in Harell's c = 0.11, P = .029). In conclusion, DEL biology is a strong and simple-to-use predictor of adverse outcome in PCNSL. Addition of DEL to the NCCN-IPI improves its prognostic potential. Disease progression from PCNSL harboring both DEL features is invariably fatal. This defines a novel PCNSL patient subset with a great unmet need for improved therapy. 相似文献
58.
59.
60.